Quantcast

Industry news that matters to you.  Learn more

DoD Announces Prostate Cancer Biomarker Development Award

Last month, the Department of Defense (DoD) announced a Prostate Cancer Research Program (PCRP) Biomarker Development Award. The award supports high-impact research aimed at qualifying or validating biomarkers for rapid transfer to clinical practice for prostate cancer.

NextGen Sciences Launches its 82 Protein Cerebrospinal Fluid (CSF) CNS Disease Biomarker Assay

NextGen Group plc is pleased to announce that its US-subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched an expanded cerebrospinal fluid (CSF) multiple protein (multiplex) assay, csfdiscovery82, for central nervous system (CNS) biomarker discovery and qualification. The new assay simultaneously measures 82 human CSF proteins that are thought to have potential as biomarkers in CNS diseases, particularly Alzheimer’s, Parkinson’s, multiple sclerosis and ALS diseases. The launch of csfdiscovery82 demonstrates the acceleration in NextGen Sciences strategy of becoming a leading player in the growing CNS biomarker market.

C-Path and The Hamner Announce Collaboration To Improve Safety of Medical Product Development

Critical Path Institute (C-Path) and The Hamner Institutes for Health Sciences (The Hamner) announced today that they have signed a Memorandum of Understanding (MOU) to develop innovative, collaborative activities in the areas of regulatory science research for predicting, detecting and monitoring liver safety issues during the development of new medicines.

NextGen Sciences Launches Multiplex Protein CSF Biomarker Assay for Alzheimer’s Disease

NextGen Group plc is pleased to announce that its US-subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched its csfalzheimers37 multiplex protein assay for Alzheimer’s disease. The assay simultaneously measures 37 human CSF (cerebrospinal fluid) proteins that are believed to have potential as biomarkers for the disease.

NextGen Sciences Agrees on a Deal with University of Nebraska Medical Center to Discover CSF Biomarkers of Cognitive Abnormality from Chronically Infected HIV Patients

NextGen Group plc is pleased to announce that its US-subsidiary NextGen Sciences Inc, has been contracted by investigators at the NIMH-funded Chronic HIV Infection and Aging in NeuroAIDS (CHAIN) Center at the University of Nebraska Medical Center (UNMC) to utilize their innovative and sensitive csfdiscovery43 assay to examine biomarkers in CSF (cerebrospinal fluid) associated with neuroAIDS. The csfdiscovery43 assay simultaneously measures 43 human CSF proteins that are thought to have potential as biomarkers in CNS (central nervous system) diseases. The goal of this project is to link the patterns of expression of these biomarkers in the CSF to cognitive abnormalities in chronically infected HIV patients.